PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma
Metastatic Melanoma

Interventions

BIOLOGICAL: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb